HRZN

Horizon Technology Finance Corp. 10-Q Summary

Business Context and Reporting Period

Company: Horizon Technology Finance Corp. (HRZN)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2017
Business Model: An externally managed, closed-end, non-diversified business development company (BDC) and regulated investment company (RIC). The company primarily makes secured debt investments (venture loans) and receives warrants in development-stage companies within the technology, life science, healthcare information and services, and cleantech sectors.

Key Financial Metrics

Material Changes vs. Prior Period

• Investment Income: Decreased 11.0% ($0.83 million) for the three months ended September 30, 2017, compared to the same period in 2016. This was primarily due to a 23.6% decrease in the average size of the investment portfolio, partially offset by higher interest rates and accelerated end-of-term payments (ETPs).
• Expenses: Total expenses decreased 9.4% ($0.31 million) for the quarter, driven by lower interest expense (due to reduced borrowings) and a lower base management fee (due to the smaller portfolio size).
• Realized Losses: The nine-month period saw a significant net realized loss of $11.10 million, primarily due to the resolution of two debt investments. This contrasts with a net realized loss of $2.86 million in the prior year's nine-month period.
• Unrealized Gains: The nine-month period recorded a net unrealized appreciation of $8.28 million, a reversal from the $14.75 million depreciation in the prior year. This was largely due to the reversal of previously recorded depreciation on two settled debt investments.
• Portfolio Composition: The portfolio shifted significantly toward the Technology sector (specifically Software and Internet/Media), which now represents a larger portion of the portfolio compared to Life Science, which decreased in relative weight.

Guidance, Outlook, and Risks

• Debt Refinancing: The company issued $32.5 million in 6.25% Senior Notes due 2022 in late September 2017. Proceeds were used to redeem the outstanding 7.375% Senior Notes due 2019 ($33.0 million) on October 30, 2017, utilizing the Key Facility credit line.
• Liquidity: As of September 30, 2017, the company had $22.3 million in cash and $95.0 million in unused commitment capacity under its Key Facility (revolving credit line), though only $65.3 million was available subject to advance rates.
• Asset Quality: Three debt investments were on non-accrual status with a cost of $16.1 million and fair value of $6.1 million. The weighted average credit rating of the debt portfolio was 3.0 (on a scale of 1-4, where 4 is highest).
• Stock Repurchase: The company repurchased 5,923 shares in the quarter at an average price of $9.97. The program allows for up to $5.0 million in repurchases and expires June 30, 2018.
• Risks: Key risks include the credit quality of portfolio companies (many are development-stage), interest rate volatility (99% of debt portfolio is floating rate), and the ability to maintain RIC status to avoid corporate-level taxation.

Investor Verification Checklist

• Debt Resolution Impact: Verify the specific details and recovery rates of the two debt investments that drove the $11.1 million realized loss in the nine-month period.
• Refinancing Terms: Confirm the final terms and costs associated with the redemption of the 2019 Notes and the issuance of the 2022 Notes, including any acceleration of unamortized debt issuance costs.
• Non-Accrual Status: Monitor the status of the three debt investments on non-accrual (ScoreBig, Digital Signal, Interleukin Genetics) and potential further write-downs.
• Portfolio Yield: Assess the sustainability of the dollar-weighted annualized yield (16.5% for the quarter) given the portfolio turnover and prepayment activity.
• Capital Deployment: Track the deployment of the $95 million available credit facility capacity to determine if the company will increase leverage to fund new investments.